The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Company to launch product after the expiry of semaglutide patent in India
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The partnership initially will focus on cardiovascular and kidney diseases
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated